ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,554.25
      0.20%
      US Tech 100
      18,971.20
      -0.03%
      Dow Jones
      40,659.76
      0.24%
      Brent Oil
      79.165
      0.00%
      Bitcoin
      59,542.88
      0.12%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Agenus Inc (AGEN)

      7. Agenus Inc (AGEN) News

      AGEN

      Agenus (AGEN)

      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AGEN
      DateTimeSourceHeadlineSymbolCompany
      08/08/20244:49PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
      08/08/20244:47PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AGENAgenus Inc
      08/08/20244:45PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
      08/08/20244:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
      08/08/20244:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGENAgenus Inc
      08/08/20247:00AMBusiness WireAgenus Reports Second Quarter 2024 Operational and Financial ResultsNASDAQ:AGENAgenus Inc
      08/08/20247:00AMBusiness WireAgenus Announces Appointment of Tom Harrison to Board of DirectorsNASDAQ:AGENAgenus Inc
      08/07/202410:58AMBusiness WireAgenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant CancersNASDAQ:AGENAgenus Inc
      08/02/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
      07/26/20247:00AMBusiness WireAgenus to Provide Second Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
      07/18/20247:00AMBusiness WireAgenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal CancerNASDAQ:AGENAgenus Inc
      06/28/202411:10AMBusiness WireSignificant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI ConferenceNASDAQ:AGENAgenus Inc
      06/27/20247:30AMBusiness WireCancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical StudiesNASDAQ:AGENAgenus Inc
      06/18/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
      06/18/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
      06/18/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
      06/18/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
      06/17/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
      06/17/20247:00AMBusiness WireAgenus Announces Appointment of Dr. Jennifer Buell to Its Board of DirectorsNASDAQ:AGENAgenus Inc
      06/14/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
      06/13/20245:15AMBusiness WireNature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50NASDAQ:AGENAgenus Inc
      06/04/20247:30AMBusiness WireAgenus Announces Virtual Annual Shareholders MeetingNASDAQ:AGENAgenus Inc
      05/30/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
      05/24/20245:00PMBusiness WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGENAgenus Inc
      05/23/20245:10PMBusiness WireBreakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual MeetingNASDAQ:AGENAgenus Inc
      05/23/20247:30AMBusiness WireAgenus to Participate in Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:AGENAgenus Inc
      05/16/20247:30AMBusiness WireFDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal CancerNASDAQ:AGENAgenus Inc
      05/07/20247:40AMBusiness WireAgenus Reports First Quarter 2024 ResultsNASDAQ:AGENAgenus Inc
      05/07/20247:39AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
      05/07/20247:38AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGENAgenus Inc
       Showing the most relevant articles for your search:NASDAQ:AGEN